Used to treat acute lymphocytic leukemia, Crohn's disease, and ulcerative colitis. Approved in US in 1953 and listed on WHO's Essential Medicines list. Generally used with methotrexate for acute lymphocytic leukemia
Bowel wall thickening can be focal (<5 cm) or segmental (6-40 cm). Normal small bowel wall thickness should not exceed 3 mm. Colonic wall thickness varies from 1-2 mm with distension to 5 mm with contraction
Crohn disease is an idiopathic inflammatory bowel disease affecting terminal ileum and proximal colon. Typically diagnosed between ages 15-25 with no gender predilection. Disease has familial component and increased risk with celiac disease
Perianal fistula is an inflammatory tract between anal sphincters. Incidence is approximately 1:10,000, with male predilection 2-4:1
FDA approved STEQEYMA (ustekinumab-stba) as biosimilar to STELARA. Approved for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Available in subcutaneous injection and intravenous infusion forms. Expected U.S. market launch in February 2025
Humira (adalimumab) is a biologic used to treat inflammatory conditions. FDA approved in 2002, it targets tumor necrosis factor (TNF)-alpha. Available as injections for subcutaneous use